ANI Pharma (ANIP) Tops Q1 EPS by 15c; Suspends FY20 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO
May 7, 2020 8:30 AM EDTBAUDETTE, Minn., May 7, 2020 /PRNewswire/ --
For the first quarter 2020, ANI reports:
Net revenues of $49.8 million versus $52.9 million in 2019 GAAP net loss of $7.0 million and diluted GAAP loss per share of $0.59 Adjusted non-GAAP EBITDA of $17.6 million Adjusted non-GAAP diluted earnings per share of $1.04Integrates Amerigen Pharmaceuticals, Ltd. portfolio
Launches five generic products increasing total commercialized product line to 60 product families
Appoints Patrick D. Walsh interim President and CEO
Suspends guidance for 2020
ANI Pharmaceuticals, Inc.... More
